protein synthesis inhibitor cycloheximide chx Search Results


96
Selleck Chemicals protein synthesis cycloheximide chx
Protein Synthesis Cycloheximide Chx, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+synthesis+inhibitor+cycloheximide+chx/pm37196484-58-3-10?v=Selleck+Chemicals
Average 96 stars, based on 1 article reviews
protein synthesis cycloheximide chx - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

96
Thermo Fisher cycloheximide
Cycloheximide, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+synthesis+inhibitor+cycloheximide+chx/pmc03365778-196-11-12?v=Thermo+Fisher
Average 96 stars, based on 1 article reviews
cycloheximide - by Bioz Stars, 2026-07
96/100 stars
  Buy from Supplier

90
Enzo Biochem protein synthesis inhibitor cycloheximide
Protein Synthesis Inhibitor Cycloheximide, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+synthesis+inhibitor+cycloheximide+chx/pmc04692422-79-18-22?v=Enzo+Biochem
Average 90 stars, based on 1 article reviews
protein synthesis inhibitor cycloheximide - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

95
Biotium 5 n ethyl n isopropyl amiloride
5 N Ethyl N Isopropyl Amiloride, supplied by Biotium, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+synthesis+inhibitor+cycloheximide+chx/pm38070134-361-117-103?v=Biotium
Average 95 stars, based on 1 article reviews
5 n ethyl n isopropyl amiloride - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

93
Valiant Co Ltd chx
Induction <t>of</t> <t>AKT</t> ubiquitination and proteasome degradation by vitamin C via a ROS-dependent pathway. Western blot analysis of total AKT in 8305C ( A ) and C643 ( B ) cells with vitamin C (VC) and cycloheximide <t>(CHX)</t> treatment alone or in combination for the indicated time points with β-Actin as a loading control. ( C ) 8305C and C643 cells was treated with 2 mM VC for 2 h after pretreatment of 25 μM MG132 for the indicated time points, and western blot analysis was then used to evaluate AKT expression. β-Actin was used as a loading control. ( D ) 8305C and C643 cells was pretreated with 25 μM MG132 for 2 h, and VC was then added for another 2 h before harvesting. Lysates were incubated with anti-AKT antibody for 4 h and then conjugated with agarose. Bounding proteins were analyzed by immunoblot with anti-ubiquitin (Ub) antibody. Input samples were taken prior to immunoprecipitation and immunoblotted with the indicated antibodies. Data were presented as mean ± SD. **, P <0.01; ***, P <0.001.
Chx, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+synthesis+inhibitor+cycloheximide+chx/pmc06599666-53-17-18?v=Valiant+Co+Ltd
Average 93 stars, based on 1 article reviews
chx - by Bioz Stars, 2026-07
93/100 stars
  Buy from Supplier

90
AG Scientific protein synthesis inhibitor cycloheximide (chx)
Induction <t>of</t> <t>AKT</t> ubiquitination and proteasome degradation by vitamin C via a ROS-dependent pathway. Western blot analysis of total AKT in 8305C ( A ) and C643 ( B ) cells with vitamin C (VC) and cycloheximide <t>(CHX)</t> treatment alone or in combination for the indicated time points with β-Actin as a loading control. ( C ) 8305C and C643 cells was treated with 2 mM VC for 2 h after pretreatment of 25 μM MG132 for the indicated time points, and western blot analysis was then used to evaluate AKT expression. β-Actin was used as a loading control. ( D ) 8305C and C643 cells was pretreated with 25 μM MG132 for 2 h, and VC was then added for another 2 h before harvesting. Lysates were incubated with anti-AKT antibody for 4 h and then conjugated with agarose. Bounding proteins were analyzed by immunoblot with anti-ubiquitin (Ub) antibody. Input samples were taken prior to immunoprecipitation and immunoblotted with the indicated antibodies. Data were presented as mean ± SD. **, P <0.01; ***, P <0.001.
Protein Synthesis Inhibitor Cycloheximide (Chx), supplied by AG Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+synthesis+inhibitor+cycloheximide+chx/10__1128_slash_ec__00099___12-96-10-12?v=AG+Scientific
Average 90 stars, based on 1 article reviews
protein synthesis inhibitor cycloheximide (chx) - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
CH Instruments protein synthesis inhibitor cycloheximide
Induction <t>of</t> <t>AKT</t> ubiquitination and proteasome degradation by vitamin C via a ROS-dependent pathway. Western blot analysis of total AKT in 8305C ( A ) and C643 ( B ) cells with vitamin C (VC) and cycloheximide <t>(CHX)</t> treatment alone or in combination for the indicated time points with β-Actin as a loading control. ( C ) 8305C and C643 cells was treated with 2 mM VC for 2 h after pretreatment of 25 μM MG132 for the indicated time points, and western blot analysis was then used to evaluate AKT expression. β-Actin was used as a loading control. ( D ) 8305C and C643 cells was pretreated with 25 μM MG132 for 2 h, and VC was then added for another 2 h before harvesting. Lysates were incubated with anti-AKT antibody for 4 h and then conjugated with agarose. Bounding proteins were analyzed by immunoblot with anti-ubiquitin (Ub) antibody. Input samples were taken prior to immunoprecipitation and immunoblotted with the indicated antibodies. Data were presented as mean ± SD. **, P <0.01; ***, P <0.001.
Protein Synthesis Inhibitor Cycloheximide, supplied by CH Instruments, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+synthesis+inhibitor+cycloheximide+chx/pmc03147959-100-0-4?v=CH+Instruments
Average 90 stars, based on 1 article reviews
protein synthesis inhibitor cycloheximide - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
Merck KGaA protein biosynthesis inhibitor cyclohexamide
Induction <t>of</t> <t>AKT</t> ubiquitination and proteasome degradation by vitamin C via a ROS-dependent pathway. Western blot analysis of total AKT in 8305C ( A ) and C643 ( B ) cells with vitamin C (VC) and cycloheximide <t>(CHX)</t> treatment alone or in combination for the indicated time points with β-Actin as a loading control. ( C ) 8305C and C643 cells was treated with 2 mM VC for 2 h after pretreatment of 25 μM MG132 for the indicated time points, and western blot analysis was then used to evaluate AKT expression. β-Actin was used as a loading control. ( D ) 8305C and C643 cells was pretreated with 25 μM MG132 for 2 h, and VC was then added for another 2 h before harvesting. Lysates were incubated with anti-AKT antibody for 4 h and then conjugated with agarose. Bounding proteins were analyzed by immunoblot with anti-ubiquitin (Ub) antibody. Input samples were taken prior to immunoprecipitation and immunoblotted with the indicated antibodies. Data were presented as mean ± SD. **, P <0.01; ***, P <0.001.
Protein Biosynthesis Inhibitor Cyclohexamide, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+synthesis+inhibitor+cycloheximide+chx/pm25749030-154-4-35?v=Merck+KGaA
Average 90 stars, based on 1 article reviews
protein biosynthesis inhibitor cyclohexamide - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

94
Gold Biotechnology Inc cycloheximide
Induction <t>of</t> <t>AKT</t> ubiquitination and proteasome degradation by vitamin C via a ROS-dependent pathway. Western blot analysis of total AKT in 8305C ( A ) and C643 ( B ) cells with vitamin C (VC) and cycloheximide <t>(CHX)</t> treatment alone or in combination for the indicated time points with β-Actin as a loading control. ( C ) 8305C and C643 cells was treated with 2 mM VC for 2 h after pretreatment of 25 μM MG132 for the indicated time points, and western blot analysis was then used to evaluate AKT expression. β-Actin was used as a loading control. ( D ) 8305C and C643 cells was pretreated with 25 μM MG132 for 2 h, and VC was then added for another 2 h before harvesting. Lysates were incubated with anti-AKT antibody for 4 h and then conjugated with agarose. Bounding proteins were analyzed by immunoblot with anti-ubiquitin (Ub) antibody. Input samples were taken prior to immunoprecipitation and immunoblotted with the indicated antibodies. Data were presented as mean ± SD. **, P <0.01; ***, P <0.001.
Cycloheximide, supplied by Gold Biotechnology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+synthesis+inhibitor+cycloheximide+chx/pm38514439-78-11-13?v=Gold+Biotechnology+Inc
Average 94 stars, based on 1 article reviews
cycloheximide - by Bioz Stars, 2026-07
94/100 stars
  Buy from Supplier

95
Valiant Co Ltd incubation with cycloheximide
Induction <t>of</t> <t>AKT</t> ubiquitination and proteasome degradation by vitamin C via a ROS-dependent pathway. Western blot analysis of total AKT in 8305C ( A ) and C643 ( B ) cells with vitamin C (VC) and cycloheximide <t>(CHX)</t> treatment alone or in combination for the indicated time points with β-Actin as a loading control. ( C ) 8305C and C643 cells was treated with 2 mM VC for 2 h after pretreatment of 25 μM MG132 for the indicated time points, and western blot analysis was then used to evaluate AKT expression. β-Actin was used as a loading control. ( D ) 8305C and C643 cells was pretreated with 25 μM MG132 for 2 h, and VC was then added for another 2 h before harvesting. Lysates were incubated with anti-AKT antibody for 4 h and then conjugated with agarose. Bounding proteins were analyzed by immunoblot with anti-ubiquitin (Ub) antibody. Input samples were taken prior to immunoprecipitation and immunoblotted with the indicated antibodies. Data were presented as mean ± SD. **, P <0.01; ***, P <0.001.
Incubation With Cycloheximide, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+synthesis+inhibitor+cycloheximide+chx/bio_rxiv__2020__06__12__146795-225-7-18?v=Valiant+Co+Ltd
Average 95 stars, based on 1 article reviews
incubation with cycloheximide - by Bioz Stars, 2026-07
95/100 stars
  Buy from Supplier

90
Enzo Biochem chx
BRM stabilizes TFIIH by promoting GTF2H1 expression. a Relative quantification of individual TFIIH genes expression in U2OS cells treated with control (CTRL) or BRM siRNAs, as determined with RT-qPCR. Individual basal gene expression in BRM knockdown was normalized to siCTRL levels, which were set to 1.0 (dotted line in graph). GAPDH expression was used for normalization. Mean & S.E.M. of at least three independent experiments. ** P < 0.01, *** P < 0.001 relative expression in each gene to siCTRL. n.s., non-significant. b Immunoblot analysis of TFIIH protein levels (GTF2H1, XPB, XPD, CCNH), TFIIEβ, DDB2 and XPC from whole cell extracts of U2OS treated with control (CTRL) or BRM siRNAs. Representative immunoblots of two independent experiments. c BRG1 and BRM co-occupancy of GTF2H1 promotor. Re-analysis of published ChIP-seq data in which ChIP-seq signal density (top) and respective peaks (bottom) illustrate BRG1 (purple) and BRM (green) enrichment at the promoter of GTF2H1 in HepG2 cells (upon shNS transfection ). Promoter region of interest highlighted in light orange, signal density in reads per million. d XPB protein stability was evaluated in U2OS cells treated with control (CTRL) or BRM siRNAs at different time points after addition of 100 µM cycloheximide <t>(CHX)</t> to inhibit <t>protein</t> <t>synthesis.</t> Immunostainings of TFIIEβ and DDB2 were used as negative and loading controls, respectively. e Quantification of XPB protein levels normalized to DDB2 in time after addition of CHX. The total amount of XPB in whole cell lysates was set to 1.0 at t = 0. Mean & S.E.M. of at least three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 for each time point of siBRM (green) or siGTF2H1 (orange) relative to siCTRL. f Relative quantification of transcription levels in U2OS cells treated with non-targeting control (CTRL), BRM, BRG1, or GTF2H1 siRNAs. Transcription was determined by measuring EU incorporation in non-irradiated cells 48 h after siRNA treatment. EU relative fluorescence intensity was set to 100% in siCTRL treated cells. Mean & S.E.M. of > 200 cells from two (siGT2H1) and three (siBRM and siBRG1) independent experiments. Full-size immunoblot scans are provided in Supplementary Fig.
Chx, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+synthesis+inhibitor+cycloheximide+chx/pmc06172278-276-8-9?v=Enzo+Biochem
Average 90 stars, based on 1 article reviews
chx - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

90
ICN Biomedicals cycloheximide (chx
BRM stabilizes TFIIH by promoting GTF2H1 expression. a Relative quantification of individual TFIIH genes expression in U2OS cells treated with control (CTRL) or BRM siRNAs, as determined with RT-qPCR. Individual basal gene expression in BRM knockdown was normalized to siCTRL levels, which were set to 1.0 (dotted line in graph). GAPDH expression was used for normalization. Mean & S.E.M. of at least three independent experiments. ** P < 0.01, *** P < 0.001 relative expression in each gene to siCTRL. n.s., non-significant. b Immunoblot analysis of TFIIH protein levels (GTF2H1, XPB, XPD, CCNH), TFIIEβ, DDB2 and XPC from whole cell extracts of U2OS treated with control (CTRL) or BRM siRNAs. Representative immunoblots of two independent experiments. c BRG1 and BRM co-occupancy of GTF2H1 promotor. Re-analysis of published ChIP-seq data in which ChIP-seq signal density (top) and respective peaks (bottom) illustrate BRG1 (purple) and BRM (green) enrichment at the promoter of GTF2H1 in HepG2 cells (upon shNS transfection ). Promoter region of interest highlighted in light orange, signal density in reads per million. d XPB protein stability was evaluated in U2OS cells treated with control (CTRL) or BRM siRNAs at different time points after addition of 100 µM cycloheximide <t>(CHX)</t> to inhibit <t>protein</t> <t>synthesis.</t> Immunostainings of TFIIEβ and DDB2 were used as negative and loading controls, respectively. e Quantification of XPB protein levels normalized to DDB2 in time after addition of CHX. The total amount of XPB in whole cell lysates was set to 1.0 at t = 0. Mean & S.E.M. of at least three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 for each time point of siBRM (green) or siGTF2H1 (orange) relative to siCTRL. f Relative quantification of transcription levels in U2OS cells treated with non-targeting control (CTRL), BRM, BRG1, or GTF2H1 siRNAs. Transcription was determined by measuring EU incorporation in non-irradiated cells 48 h after siRNA treatment. EU relative fluorescence intensity was set to 100% in siCTRL treated cells. Mean & S.E.M. of > 200 cells from two (siGT2H1) and three (siBRM and siBRG1) independent experiments. Full-size immunoblot scans are provided in Supplementary Fig.
Cycloheximide (Chx, supplied by ICN Biomedicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/protein+synthesis+inhibitor+cycloheximide+chx/pmc02675628-110-3-10?v=ICN+Biomedicals
Average 90 stars, based on 1 article reviews
cycloheximide (chx - by Bioz Stars, 2026-07
90/100 stars
  Buy from Supplier

Image Search Results


Induction of AKT ubiquitination and proteasome degradation by vitamin C via a ROS-dependent pathway. Western blot analysis of total AKT in 8305C ( A ) and C643 ( B ) cells with vitamin C (VC) and cycloheximide (CHX) treatment alone or in combination for the indicated time points with β-Actin as a loading control. ( C ) 8305C and C643 cells was treated with 2 mM VC for 2 h after pretreatment of 25 μM MG132 for the indicated time points, and western blot analysis was then used to evaluate AKT expression. β-Actin was used as a loading control. ( D ) 8305C and C643 cells was pretreated with 25 μM MG132 for 2 h, and VC was then added for another 2 h before harvesting. Lysates were incubated with anti-AKT antibody for 4 h and then conjugated with agarose. Bounding proteins were analyzed by immunoblot with anti-ubiquitin (Ub) antibody. Input samples were taken prior to immunoprecipitation and immunoblotted with the indicated antibodies. Data were presented as mean ± SD. **, P <0.01; ***, P <0.001.

Journal: Theranostics

Article Title: Vitamin C kills thyroid cancer cells through ROS-dependent inhibition of MAPK/ERK and PI3K/AKT pathways via distinct mechanisms

doi: 10.7150/thno.35219

Figure Lengend Snippet: Induction of AKT ubiquitination and proteasome degradation by vitamin C via a ROS-dependent pathway. Western blot analysis of total AKT in 8305C ( A ) and C643 ( B ) cells with vitamin C (VC) and cycloheximide (CHX) treatment alone or in combination for the indicated time points with β-Actin as a loading control. ( C ) 8305C and C643 cells was treated with 2 mM VC for 2 h after pretreatment of 25 μM MG132 for the indicated time points, and western blot analysis was then used to evaluate AKT expression. β-Actin was used as a loading control. ( D ) 8305C and C643 cells was pretreated with 25 μM MG132 for 2 h, and VC was then added for another 2 h before harvesting. Lysates were incubated with anti-AKT antibody for 4 h and then conjugated with agarose. Bounding proteins were analyzed by immunoblot with anti-ubiquitin (Ub) antibody. Input samples were taken prior to immunoprecipitation and immunoblotted with the indicated antibodies. Data were presented as mean ± SD. **, P <0.01; ***, P <0.001.

Article Snippet: To assess the effect of vitamin C on AKT protein stability, cells were incubated with 200 µg/mL CHX (MP Biomedicals, Santa Ana, CA) for 2 h to inhibit de novo protein synthesis, and then treated with 2 mM vitamin C. At the indicated time points, cell lysates were harvested and subjected to Western blot analysis using the indicated antibodies.

Techniques: Western Blot, Expressing, Incubation, Immunoprecipitation

BRM stabilizes TFIIH by promoting GTF2H1 expression. a Relative quantification of individual TFIIH genes expression in U2OS cells treated with control (CTRL) or BRM siRNAs, as determined with RT-qPCR. Individual basal gene expression in BRM knockdown was normalized to siCTRL levels, which were set to 1.0 (dotted line in graph). GAPDH expression was used for normalization. Mean & S.E.M. of at least three independent experiments. ** P < 0.01, *** P < 0.001 relative expression in each gene to siCTRL. n.s., non-significant. b Immunoblot analysis of TFIIH protein levels (GTF2H1, XPB, XPD, CCNH), TFIIEβ, DDB2 and XPC from whole cell extracts of U2OS treated with control (CTRL) or BRM siRNAs. Representative immunoblots of two independent experiments. c BRG1 and BRM co-occupancy of GTF2H1 promotor. Re-analysis of published ChIP-seq data in which ChIP-seq signal density (top) and respective peaks (bottom) illustrate BRG1 (purple) and BRM (green) enrichment at the promoter of GTF2H1 in HepG2 cells (upon shNS transfection ). Promoter region of interest highlighted in light orange, signal density in reads per million. d XPB protein stability was evaluated in U2OS cells treated with control (CTRL) or BRM siRNAs at different time points after addition of 100 µM cycloheximide (CHX) to inhibit protein synthesis. Immunostainings of TFIIEβ and DDB2 were used as negative and loading controls, respectively. e Quantification of XPB protein levels normalized to DDB2 in time after addition of CHX. The total amount of XPB in whole cell lysates was set to 1.0 at t = 0. Mean & S.E.M. of at least three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 for each time point of siBRM (green) or siGTF2H1 (orange) relative to siCTRL. f Relative quantification of transcription levels in U2OS cells treated with non-targeting control (CTRL), BRM, BRG1, or GTF2H1 siRNAs. Transcription was determined by measuring EU incorporation in non-irradiated cells 48 h after siRNA treatment. EU relative fluorescence intensity was set to 100% in siCTRL treated cells. Mean & S.E.M. of > 200 cells from two (siGT2H1) and three (siBRM and siBRG1) independent experiments. Full-size immunoblot scans are provided in Supplementary Fig.

Journal: Nature Communications

Article Title: DNA damage sensitivity of SWI/SNF-deficient cells depends on TFIIH subunit p62/GTF2H1

doi: 10.1038/s41467-018-06402-y

Figure Lengend Snippet: BRM stabilizes TFIIH by promoting GTF2H1 expression. a Relative quantification of individual TFIIH genes expression in U2OS cells treated with control (CTRL) or BRM siRNAs, as determined with RT-qPCR. Individual basal gene expression in BRM knockdown was normalized to siCTRL levels, which were set to 1.0 (dotted line in graph). GAPDH expression was used for normalization. Mean & S.E.M. of at least three independent experiments. ** P < 0.01, *** P < 0.001 relative expression in each gene to siCTRL. n.s., non-significant. b Immunoblot analysis of TFIIH protein levels (GTF2H1, XPB, XPD, CCNH), TFIIEβ, DDB2 and XPC from whole cell extracts of U2OS treated with control (CTRL) or BRM siRNAs. Representative immunoblots of two independent experiments. c BRG1 and BRM co-occupancy of GTF2H1 promotor. Re-analysis of published ChIP-seq data in which ChIP-seq signal density (top) and respective peaks (bottom) illustrate BRG1 (purple) and BRM (green) enrichment at the promoter of GTF2H1 in HepG2 cells (upon shNS transfection ). Promoter region of interest highlighted in light orange, signal density in reads per million. d XPB protein stability was evaluated in U2OS cells treated with control (CTRL) or BRM siRNAs at different time points after addition of 100 µM cycloheximide (CHX) to inhibit protein synthesis. Immunostainings of TFIIEβ and DDB2 were used as negative and loading controls, respectively. e Quantification of XPB protein levels normalized to DDB2 in time after addition of CHX. The total amount of XPB in whole cell lysates was set to 1.0 at t = 0. Mean & S.E.M. of at least three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 for each time point of siBRM (green) or siGTF2H1 (orange) relative to siCTRL. f Relative quantification of transcription levels in U2OS cells treated with non-targeting control (CTRL), BRM, BRG1, or GTF2H1 siRNAs. Transcription was determined by measuring EU incorporation in non-irradiated cells 48 h after siRNA treatment. EU relative fluorescence intensity was set to 100% in siCTRL treated cells. Mean & S.E.M. of > 200 cells from two (siGT2H1) and three (siBRM and siBRG1) independent experiments. Full-size immunoblot scans are provided in Supplementary Fig.

Article Snippet: Protein synthesis was inhibited by adding 100 μM CHX (Enzo) to cells in culture.

Techniques: Expressing, Quantitative Proteomics, Control, Quantitative RT-PCR, Gene Expression, Knockdown, Western Blot, ChIP-sequencing, Transfection, Irradiation, Fluorescence